AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03946163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
Study NCT03410225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMI-TPP
Description: The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
Study NCT03410225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAMI-Fitness
Description: The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
Study NCT00745914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
Study NCT00745914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study NCT00808769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zegerid®
Description: capsule(20 mg omeprazole/sodium bicarbonate), single dose
Study NCT00808769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec OTC®
Description: Omeprazole-magnesium 20.6 mg, tablet, single dose
Study NCT01076140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Study NCT01076140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Study NCT01846039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked hyaluronic acid gel
Description: Up to 3 mL administered by intradermal injection
Study NCT01433029 — intervention group
Intervention type: OTHER
Intervention: Surgical Video Assessments
Description: Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
Study NCT01433029 — intervention group
Intervention type: OTHER
Intervention: Video Recording of CAB
Description: Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
Study NCT06335394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NVD003
Description: Autologous osteogenic implant NVD-003 for bone reconstruction
Study NCT04882956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: Brolucizumab-Dbll intravitreal injection
Study NCT05045339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ball Exercises
Description: Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
Study NCT04760639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Participants provide a breath sample
Study NCT03225313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
Description: ultra sound guided injection into the rectus sheath
Study NCT03225313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution_#5
Description: injected into rectus sheath using ultrasound \& locally surrounding the hernia
Study NCT03225313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
Description: locally surrounding the hernia
Study NCT01682681 — intervention group
Intervention type: DRUG
Intervention: Topiramate
Description: This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
Study NCT02231606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Glasses
Description: Provide free glasses
Study NCT02231606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upgrade Glasses 1
Description: Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
Study NCT02231606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upgrade Glasses 2
Description: Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
Study NCT03832426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg film-coated tablets
Study NCT03832426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg film-coated tablets
Study NCT02558634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM Thalamic Deep Brain Stimulation ON
Study NCT02558634 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VIM Thalamic Deep Brain Stimulation OFF
Study NCT01891669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263507
Description: Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
Study NCT01891669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263507
Description: Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study NCT01927159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Study NCT01927159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02766868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACE-Flu/Bu/Cy
Description: Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
Study NCT03564613 — intervention group
Intervention type: DRUG
Intervention: DTG
Description: Subjects with DTG exposure during any trimester will be included
Study NCT04078347 — intervention group
Intervention type: PROCEDURE
Intervention: Paravertebral block at T4 and T5 level
Description: Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
Study NCT02650089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Low intensity
Description: The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
Study NCT02650089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise High intensity
Description: The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
Study NCT02650089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
Study NCT00657644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa will be administered as per approved label.
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa will be administered as per approved label.
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered as per approved label.
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered as per approved label.
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Beta
Description: Epoetin beta will be administered as per approved label.
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methoxy polyethylene glycol-epoetin beta
Description: Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
Study NCT00773513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
Study NCT04104737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spire Medical Health Tag
Description: Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References.
Study NCT03796065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FSI-R Treatment
Description: The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
Study NCT00346125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
Study NCT00346125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
Study NCT00346125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: 9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1
Study NCT03265626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1: Comprehensive preventive intervention
Description: aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
Study NCT01993238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)
Description: Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
Study NCT01993238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-treatment analgesia
Description: Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
Study NCT02303275 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Change
Description: Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes.
Study NCT02303275 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Change
Description: The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
Study NCT00346125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: 45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
Study NCT03225339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Energy Diet
Description: Low Energy Diet
Study NCT03651440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF
Study NCT03651440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar stabilization training
Description: lumbar stabilization training
Study NCT03651440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical Therapy
Study NCT03651440 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control group
Study NCT03384576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Classical music to be played in the Emergency waiting room
Study NCT03384576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No music
Description: No music played in emergency waiting room
Study NCT00346125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: The surgical procedure will be decided by the treating physician and independent of study participation
Study NCT01786837 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Functional Magnetic Stimulation
Description: 20 minute stimulation will be applied 5 days a week for 5 weeks
Study NCT01786837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation
Description: 20 minute stimulation will be applied 5 days a week for 5 weeks
Study NCT04818866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
Description: Biomarkers of inflammation
Study NCT02464176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
Study NCT02464176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be used in lumbar plexus nerve block mixture.
Study NCT02464176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be used in lumbar plexus nerve block mixture.
Study NCT02464176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine will be used in lumbar plexus nerve block mixture.
Study NCT02464176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine will be used in lumbar plexus nerve block mixture.
Study NCT02464176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Plexus Nerve Block
Description: This is the procedure that will be performed.
Study NCT02464176 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lumbar Plexus Nerve Block
Description: This is the procedure that will be performed.
Study NCT02464176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients randomized to the placebo group will receive normal saline intravenously.
Study NCT04939337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-SC01
Description: Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
Study NCT01211158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol
Description: Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
Study NCT01211158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol alone
Description: Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
Study NCT03257800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
Study NCT03257800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
Study NCT01042288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Study NCT01042288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Study NCT01042288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Study NCT03205163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advate (Low Dose)
Description: Participants received a single IV low dose of Advate 25 IU/kg.
Study NCT03205163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advate (High Dose)
Description: Participants received a single IV high dose of Advate 65 IU/kg.
Study NCT03205163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIVV001 (Low Dose)
Description: Participants received single IV low dose of BIVV001 25 IU/kg.
Study NCT04882956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: Aflipercept intravitreal injection